Your browser doesn't support javascript.
loading
IL-6-based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts.
Utrero-Rico, Alberto; Ruiz-Hornillos, Javier; González-Cuadrado, Cecilia; Rita, Claudia Geraldine; Almoguera, Berta; Minguez, Pablo; Herrero-González, Antonio; Fernández-Ruiz, Mario; Carretero, Octavio; Taracido-Fernández, Juan Carlos; López-Rodriguez, Rosario; Corton, Marta; Aguado, José María; Villar, Luisa María; Ayuso-García, Carmen; Paz-Artal, Estela; Laguna-Goya, Rocio.
Afiliação
  • Utrero-Rico A; Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • Ruiz-Hornillos J; Allergy Unit, Hospital Infanta Elena, Valdemoro, Madrid, Spain; Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain; Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.
  • González-Cuadrado C; Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • Rita CG; Department of Immunology, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.
  • Almoguera B; Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
  • Minguez P; Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
  • Herrero-González A; Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
  • Fernández-Ruiz M; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Carretero O; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Taracido-Fernández JC; Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
  • López-Rodriguez R; Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
  • Corton M; Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
  • Aguado JM; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Madrid, Spain; Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
  • Villar LM; Department of Immunology, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.
  • Ayuso-García C; Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
  • Paz-Artal E; Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Department of Immunology, Ophthalmology and ENT, Universidad Complutense de Madrid, Madrid, Spain.
  • Laguna-Goya R; Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. Electronic address: rocio.laguna@salud.madrid.org.
J Allergy Clin Immunol ; 147(5): 1652-1661.e1, 2021 05.
Article em En | MEDLINE | ID: mdl-33662370
ABSTRACT

BACKGROUND:

Coronavirus disease 2019 (COVID-19) is a highly variable condition. Validated tools to assist in the early detection of patients at high risk of mortality can help guide medical decisions.

OBJECTIVE:

We sought to validate externally, as well as in patients from the second pandemic wave in Europe, our previously developed mortality prediction model for hospitalized COVID-19 patients.

METHODS:

Three validation cohorts were generated 2 external with 185 and 730 patients from the first wave and 1 internal with 119 patients from the second wave. The probability of death was calculated for all subjects using our prediction model, which includes peripheral blood oxygen saturation/fraction of inspired oxygen ratio, neutrophil-to-lymphocyte ratio, lactate dehydrogenase, IL-6, and age. Discrimination and calibration were evaluated in the validation cohorts. The prediction model was updated by reestimating individual risk factor effects in the overall cohort (N = 1477).

RESULTS:

The mortality prediction model showed good performance in the external validation cohorts 1 and 2, and in the second wave validation cohort 3 (area under the receiver-operating characteristic curve, 0.94, 0.86, and 0.86, respectively), with excellent calibration (calibration slope, 0.86, 0.94, and 0.79; intercept, 0.05, 0.03, and 0.10, respectively). The updated model accurately predicted mortality in the overall cohort (area under the receiver-operating characteristic curve, 0.91), which included patients from both the first and second COVID-19 waves. The updated model was also useful to predict fatal outcome in patients without respiratory distress at the time of evaluation.

CONCLUSIONS:

This is the first COVID-19 mortality prediction model validated in patients from the first and second pandemic waves. The COR+12 online calculator is freely available to facilitate its implementation (https//utrero-rico.shinyapps.io/COR12_Score/).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-6 / Modelos Imunológicos / SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-6 / Modelos Imunológicos / SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article